Studying stroke risk in atrial fibrillation patients taking blood-thinning tablets
Observes stroke risk in adults with atrial fibrillation who take direct oral anticoagulants.
Plain-language title generated from the registry record
Registry title: Risk Score of Embolism in Patients With AF Undergoing DOAC Therapy
Key facts
- Where
- Barcelona, SpainSee the 2 sites
Where in Spain
- Germans Trias University HospitalBarcelona, SpainTaking people
- Vall d'Hebron University HospitalBarcelona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Universitari Vall d'Hebron Research Institute
- Trial code
- NCT07713537
- Record updated
- 20 July 2026
- Original description
Acute ischaemic strokes occur despite the use of direct oral anticoagulants (DOACs). Evidence-based scale is necessary to assess ischemic stroke risk in atrial fibrillation (AF) patients.Read full original descriptionShow less
Risk Score of Embolism in Patients With Atrial Fibrillation (AF) Undergoing Treatment With Direct Oral Anticoagulant (DOAC)
Acute ischaemic strokes occur despite the use of direct oral anticoagulants (DOACs). Evidence-based scale is necessary to assess ischemic stroke risk in atrial fibrillation (AF) patients.
Inclusion: Patient over 18 years of age; History of AD; Currently on DOACs; Capacity to understand the study procedures and provide informed consent.
Exclusion: Patient with valvular AF (mitral stenosis) or mechanical valve prostheses; Unable to complete a follow-up period of at least 3 months from enrollment.